Theriva Biologics (NYSEAMERICAN:TOVX) Trading 5.2% Higher – Here’s Why

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX)’s share price was up 5.2% during mid-day trading on Tuesday . The stock traded as high as $0.2187 and last traded at $0.2029. Approximately 6,389,528 shares changed hands during trading, an increase of 127% from the average daily volume of 2,820,571 shares. The stock had previously closed at $0.1929.

Theriva Biologics Stock Performance

The stock has a market capitalization of $6.85 million, a P/E ratio of -0.01 and a beta of 0.34. The stock’s 50-day simple moving average is $0.27 and its 200 day simple moving average is $0.38. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.90 and a quick ratio of 0.90.

Theriva Biologics (NYSEAMERICAN:TOVX) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.45) earnings per share for the quarter.

Hedge Funds Weigh In On Theriva Biologics

A hedge fund recently bought a new stake in Theriva Biologics stock. Two Sigma Investments LP purchased a new position in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 61,837 shares of the company’s stock, valued at approximately $25,000. Two Sigma Investments LP owned about 0.64% of Theriva Biologics at the end of the most recent quarter. 6.17% of the stock is currently owned by institutional investors.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.